SecBot SecBot
S-3 ·Filed Mar 20, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed8mo ago SEC0001213900-26-032416
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

Traders should anticipate significant dilution from this offering and monitor for actual issuance of shares. The stock is likely to face downward pressure as the market prices in the dilutive capital raise. Watch for any updates on the BayMedica business and the company's ability to secure additional funding.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.7610
T+0 close · Mar 20, 2026 · via day close
Latest settled
+95.80%
T+60 · $1.49
Vs SPY
+82.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $0.7610entry
  2. T+1 · 8mo ago −9.07%α −8.71% · $0.6920
  3. T+5 · 8mo ago −19.19%α −15.62% · $0.6150
  4. T+20 · 7mo ago −5.26%α −12.68% · $0.7210
  5. T+60 · 5mo ago +95.80%α +82.74% · $1.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals has filed an S-3 shelf registration statement allowing it to raise up to $50 million through future offerings of common shares, preferred shares, warrants, subscription rights, or units. This signals a potential capital raise, which could lead to significant shareholder dilution given the company's current $2 million market cap. The filing comes amid ongoing operating losses and substantial doubt about the company's ability to continue as a going concern, particularly due to adverse U.S. legislation impacting its BayMedica commercial business.

Key Financial Metrics

Offering Size
$50.0M
Dilution
2500%

Key Facts

  • InMed filed an S-3 shelf registration allowing for up to $50 million in future securities offerings.
  • The company's market cap is only $2 million, meaning the offering could result in massive dilution of up to 2,500%.
  • InMed has recurring operating losses and an accumulated deficit, with auditors noting substantial doubt about its ability to continue as a going concern.
  • The company's BayMedica commercial business faces material adverse impact from recent U.S. legislation affecting its cannabinoid inventory.
  • InMed expects its current cash of $7 million to last only until Q4 2026, creating urgency for additional financing.

Financial Impact

The $50 million offering could dilute existing shareholders by up to 2,500% given the current $2 million market cap. The company has $7 million in cash but is burning cash at a rate of approximately $4 million per six months.

dilutioncashFlowmarketCapdebt

Risk Factors

  • Massive shareholder dilution from the $50 million offering against a $2 million market cap
  • Substantial doubt about the company's ability to continue as a going concern
  • Adverse U.S. legislation threatening the BayMedica commercial business
  • Continuing operating losses and negative cash flow

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001213900-26-032416
Document: ea028202601ex-fee.htm0001213900-26-032416
Document: ea028202601ex5-1.htm0001213900-26-032416
Document: ea028202601ex23-2.htm0001213900-26-032416
Document: ea028202601ex23-1.htm0001213900-26-032416
Document: 0001213900-26-032416-index-headers.html0001213900-26-032416
Document: 0001213900-26-032416-index.html0001213900-26-032416
Document: 0001213900-26-032416.txt0001213900-26-032416
CONTEXT: 10-Q (2026-02-11)0001213900-26-014996

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 20, 2026